Encorium Selected Partner For Clinical Development of Next Generation Oncolytic Viruses in Cancer Therapy

Encorium has been selected partner for a European Biotechnological drug development company entering PI/II. The company has a unique approach in treatment of solid cancer tumors. Encorium has already been consulting the company for its regulatory strategies and supported the company in the scientific advice process. The clinical study is estimated to start in early autumn.